Your browser doesn't support javascript.
loading
COVID-19: IgG seroconversion under intensive glucocorticoid treatment in a high-risk patient with minimal change disease.
Eder, Michael; Strassl, Robert; Kläger, Johannes; Aigner, Christof; Thalhammer, Florian; Kikic, Zeljko.
Afiliação
  • Eder M; Department of Internal Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.
  • Strassl R; Division of Clinical Virology, Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
  • Kläger J; Department of Pathology, Medical University of Vienna, Vienna, Austria.
  • Aigner C; Department of Internal Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.
  • Thalhammer F; Department of Internal Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria.
  • Kikic Z; Department of Internal Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria. zeljko.kikic@meduniwien.ac.at.
Wien Klin Wochenschr ; 133(7-8): 412-413, 2021 Apr.
Article em En | MEDLINE | ID: mdl-33289854
In this case report we present a rare case of a patient with multiple risk factors for severe coronavirus disease (COVID 19) in whom intensive glucocorticoid treatment due to incipient nephrotic syndrome coincided with SARS-CoV­2 infection. Despite this high baseline risk profile and the use of glucocorticoids the patient developed only mild disease including IgG SARS-CoV­2 seroconversion.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 / Nefrose Lipoide Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 / Nefrose Lipoide Idioma: En Ano de publicação: 2021 Tipo de documento: Article